The Lancet: Three in five liver cancer cases due to preventable risk factors; obesity-linked cases on the rise, new analysis suggest
Peer-Reviewed Publication
Updates every hour. Last Updated: 11-Sep-2025 22:11 ET (12-Sep-2025 02:11 GMT/UTC)
The majority of liver cancer cases could be prevented by reducing levels of viral hepatitis, alcohol consumption and MASLD (metabolic dysfunction-associated steatotic liver disease – previously called non-alcoholic fatty liver disease), suggests an analysis as part of The Lancet Commission on liver cancer. The Commission highlights several ways to reduce these risks factors, including increasing the coverage of the hepatitis B vaccine and public health policies targeting obesity and alcohol consumption.
A precise timing of existing treatments could significantly improve treatment outcomes for one of the most aggressive cancers, suggests new research from researchers at UC San Diego.
This editorial reviews Decker et al’s study of more than 100,000 veterans experiencing homelessness who were overdue for colorectal or breast cancer screening. About 57,000 secured housing during a 24-month window and were more than twice as likely to get screened after doing so.
This study examines if gaining housing increased rates of colorectal and breast cancer screening in a cohort of veterans who experience homelessness.
The brain’s health depends on more than just its neurons. A complex network of blood vessels and immune cells acts as the brain’s dedicated guardians—controlling what enters, cleaning up waste, and protecting it from threats by forming the blood-brain barrier. A new study from Gladstone Institutes reveals that many genetic risk factors for neurological diseases like Alzheimer’s and stroke exert their effects within these very guardian cells.
Melanoma testing could one day be done at home with a skin patch and test strip with two lines, similar to COVID-19 home tests, according to University of Michigan researchers.
A groundbreaking review by researchers at Central South University highlights six critical signaling pathways—CCNE1/CDK2, MYC/CDK9, CDK4/CDK6/FOXM1, PTEN/PI3K/AKT/mTOR, AURKB, and VEGFA/VEGFR—as promising targets for osteosarcoma (OS) treatment. The study underscores the potential of network-based drug discovery to combat this aggressive bone cancer.
While chemotherapy remains a cornerstone of lung cancer treatment, it often weakens the immune system it relies on for long-term control.